Hypertrophy Arrhythmia Oxygen Consumption Vasoconstriction Atherosclerosis Insulin Resistance Renal Sympathetic Afferent Nerves: Kidney as Origin of Central.

Slides:



Advertisements
Similar presentations
ARTERIAL BLOOD PRESSURE REGULATION
Advertisements

RDN for hypertension: Physiological rationale Dr.C.Venkata S.Ram.
RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
Treatment-Resistant Hypertension: Pathophysiology Power Over Pressure
Treatment-Resistant Hypertension: Management Approaches Power Over Pressure
Hypertension What to do when you don’t know what to do! Fiona Stewart Auckland Heart Group Auckland City Hospital 2 nd Sept 2011.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Cardiovascular System II. How do we measure blood pressure ?
Ali Zahedmehr, Interventional Cardiologist Shahid Rajaie Cardiovascular medical and research center.
Temi caldi in Nefrologia La denervazione dell’arteria renale nel trattamento dell’ipertensione arteriosa Luigi Amoroso UOC Nefrologia e Dialisi Ospedale.
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
1 Chronic Treatment of Resistant Hypertension with an Implantable Medical Device: Interim 3 Year Results of Two Studies of the Rheos ® Hypertension System.
Medtronic CardioVascular Interventional Pipeline 1.
No disclosures relevant to this topic
Blood Pressure and Hypertension. Blood Pressure Your Blood Pressure Reflects: 1)How hard your heart is working 2)The condition of your arteries.
A Controlled Trial of Renal Denervation for Resistant Hypertension
Antihypertensive Drugs
Human Anatomy and Physiology
Renal denervation for resistant hypertension: it’s time to reconsider!
강동경희대학교병원 심장혈관센터 김종진 Renal Nerve Denervation in Resistant Hypertension.
Radial Frequency Ablation for Hypertension Treatment: Help or Hype? J. Dawn Abbott, M.D., F.A.C.C., F.S.C.A.I. Director, Interventional Cardiology Fellowship.
Date of download: 6/21/2016 From: Pathogenesis of Hypertension Ann Intern Med. 2003;139(9): doi: / A pathway.
Blood Pressure.
Renal Sympathetic Denervation View From the EU
Meeting of the Balkan Excellent Centers
Prairie Cardiovascular, Springfield, IL US
Pre-Clinical Models and Clinical Studies to
Renal Nerve Ablation: Will It Become the treatment
Thomas F. Lüscher, FESC, FAHA, FRCP
Applications beyond hypertension management
Catheter-Based Denervation for Resistant Hypertension
Catheter-based Renal Denervation with the Symplicity System Provides Safe and Durable Blood Pressure Reduction out to Three Years Horst Sievert1, Henry.
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Critical Appraisal of the Current Ongoing Study Designs
Renal Denervation for Congestive Heart Failure
John C. Somberg, MD I have no real or apparent conflicts of interest to report.
From ESH 2016 | POS 7D: Jan Rosa, MD
Sympathetic Nerve Denervation for Treatment of Hypertension
Simplicity Denervation System for Pulmonary Artery Denervation in Patients with Residual Pulmonary Hypertension after Pulmonary Thromboembolism and.
Accelerating a Revolution in the Treatment of Hypertension
Beyond RDN Paul A. Sobotka, MD Professor of Medicine/Cardiology
A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy.
Renal Artery Brachytherapy for Sympathetic Renal Denervation for the Treatment of Resistant Hypertension: Preclinical safety study Ron Waksman, Issi Barbash,
Mapping Sympathetic Nerve Distribution for
Chemical Renal Denervation Update and Future Directions
Renal Denervation for Non-Hypertensive Indications
Renal Nerve Stimulation for Treatment of Neurocardiogenic Syncope
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Neuro-Hormonal vs Structural Hypertension why they require different approaches Paul A. Sobotka Chief Medical Officer Rox Medical, Inc.
Baroreflex activatie therapie
The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,
Renal Sympathetic Denervation: The Academic View
CVRx Baroreflex Activation Therapy:
Animal Models and Physiologic Models And Physiologic Assessment
Renal Denervation as a Therapeutic Approach for Hypertension
Emerging Mechanisms in Glucose Metabolism
Thank you for taking the preassessment
Resistant Hypertension: Initial Combinations of Medications
Renal Denervation Industry Perspective
cardiovascular and renal systems
Controlling Elevated Blood Pressure
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Urinary Indices and Microscopy in Sepsis-Related Acute Renal Failure
Volume 377, Issue 9771, Pages (March 2011)
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Exposure to intermittent hypoxia after 13 nights led to an increase in sympathetic activity measured by muscle sympathetic nerve activity (MSNA). Exposure.
Jens Jordan, Johannes F. Mann, Friedrich C. Luft  Kidney International 
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.
Presentation transcript:

Hypertrophy Arrhythmia Oxygen Consumption Vasoconstriction Atherosclerosis Insulin Resistance Renal Sympathetic Afferent Nerves: Kidney as Origin of Central Sympathetic Drive Renal Afferent Nerves ↑ Renin Release  RAAS activation ↑ Sodium Retention ↓ Renal Blood Flow Sleep Disturbances 1

Standard interventional technique 4-6 two-minute treatments per artery Proprietary RF Generator − Automated − Low-power − Built-in safety algorithms Renal Nerve Anatomy Allows a Catheter-Based Approach In the United States: Caution: Investigational Device. Limited by U.S. law to investigational use. 2

Significant, Sustained BP Reduction BP change (mmHg) Sievert et al. European Society of Cardiology

Norepinephrine Spillover Muscle Sympathetic Nerve Activity (MSNA) Central Sympathetic Nerve Activity Renal Sympathetic Nerve Activity 4 Proof of Principle

Reduction of Renal Contribution to Central Sympathetic Drive: MSNA in Resistant Hypertension Patient Baseline 1 mo 12 mo MSNA (burst/min) BP (mmHg) 56  161/ (-27%)  141/90 (-20/-17) 19 (-66%)  127/81 (-34/-26) Schlaich et al. NEJM. 2009; 36(9): * Improvement in cardiac baroreflex sensitivity after renal denervation (7.8  11.7 msec/mmHg) * 59 year old male on 7 HTN meds 5

Renal Norepinephrine Spillover: 10 cases Example Case: Left: 75 % reduction Right: 85 % reduction Esler et al. J Htn. 2009;27(suppl 4):s167. Schlaich et al. J Htn. 2009;27(suppl 4):s154. Mean total renal norepinephrine spillover ↓ 47%, p=0.023 (95% CI: 28–65%) Mean total body NE spillover ↓ 28%, p=0.043 (95% CI: 4–52%) 6